
FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The U.S. Food and Drug Administration (FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments.
The agency announced the action on Friday, citing serious safety concerns and "unreasonable and significant risk" to study participants. The FDA also revoked the company's platform technology designation and requested Sarepta voluntarily halt shipments of its approved drug Elevidys, which the company refused to do.
Newsweek reached out to Sarepta Therapeutics via email on Sunday after normal business hours for comment.
Why It Matters
This regulatory intervention represents a significant safety measure in the gene therapy field, affecting both ongoing clinical trials and an already approved treatment for Duchenne muscular dystrophy.
The decision could impact treatment options for families dealing with these devastating muscle-wasting diseases. Duchenne muscular dystrophy is a rare and serious genetic condition that worsens over time, leading to weakness and wasting away of the body's muscles.
What To Know
The three deaths resulted from acute liver failure in patients treated with either Elevidys or investigational therapies using the same AAVrh74 viral vector technology. One fatality occurred during a clinical trial for limb girdle muscular dystrophy treatment.
Elevidys is an adeno-associated virus vector-based gene therapy designed to deliver a gene that leads to production of a shortened protein that contains selected domains of the dystrophin protein present in normal muscle cells. The disease occurs due to a defective gene that results in abnormalities in, or absence of, dystrophin, a protein that helps keep the body's muscle cells intact.
The drug received traditional approval for ambulatory DMD patients aged 4 and older on June 20, 2024, while maintaining accelerated approval for non-ambulatory patients since June 22, 2023. Under accelerated approval, companies must conduct confirmatory studies to verify clinical benefit. Given the new safety concerns, the FDA has notified Sarepta that the drug's indication should be restricted to ambulatory patients only.
The FDA revoked the platform technology designation for Sarepta's AAVrh74 Platform Technology because the preliminary evidence is insufficient to demonstrate that the technology has the potential to be incorporated in multiple drugs without adverse safety effects.
What People Are Saying
FDA Commissioner Marty Makary, M.D., M.P.H.: "Today, we've shown that this FDA takes swift action when patient safety is at risk. We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges."
Dr. Vinay Prasad, Director of FDA's Center for Biologics Evaluation and Research: "Protecting patient safety is our highest priority, and the FDA will not allow products whose harms are greater than benefits. The FDA will halt any clinical trial of an investigational product if clinical trial participants would be exposed to an unreasonable and significant risk of illness or injury."
FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025.
FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025.
AP Photo/Jose Luis Magana, File
What Happens Next
The FDA will continue investigating the risk of acute liver failure and other serious outcomes following gene therapies using Sarepta's AAVrh74 platform technology. The agency has committed to taking additional regulatory actions as needed to protect patients.
For current Elevidys patients, the FDA is focusing its safety investigation on ambulatory patients while restricting the drug's use in non-ambulatory patients.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Esperion to Report Second Quarter 2025 Financial Results on August 5
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on LinkedIn and X. Esperion Contact Information: Investors: Alina Veneziainvestorrelations@ (734) 887-3903 Media: Tiffany Aldrich corporateteam@ (616) 443-8438Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Newsweek
12 minutes ago
- Newsweek
'Forever Chemicals' Detected in Reusable Feminine Hygiene Products
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Reusable menstrual products—once hailed as eco-friendly and health-conscious alternatives to disposables—may be hiding a chemical threat, according to a new study. Researchers from Indiana University and the University of Notre Dame have discovered evidence of per- and polyfluoroalkyl substances (PFAS), commonly known as "forever chemicals," in a wide range of reusable feminine hygiene products. The study involved the testing of 59 products from North America, South America and Europe. These included period underwear, reusable pads, menstrual cups and reusable incontinence underwear. A stock image of women's underwear, reusable cloth pad and menstrual cup on a violet background. A stock image of women's underwear, reusable cloth pad and menstrual cup on a violet background. Liudmila Chernetska/iStock / Getty Images Plus Last year, researchers led from the Harvard T.H. Chan School of Public Health in Boston analyzed menstrual hygiene habits using data from the Apple Women's Health Study, which tracked 11,455 U.S. participants between November 2019 and January 2024. Despite rising awareness about arsenic and toxic metals, regular tampons remained the most commonly used menstrual product, used by 48 percent of subjects. Pads were used by 47 percent and panty liners by 43 percent. Among reusable options, period underwear was chosen by 20 percent and menstrual cups by 18 percent of respondents. Recently, the researches found PFAS were detected in nearly 30 percent of the samples—at levels suggesting they were intentionally added. This marks the first official confirmation of these potentially harmful chemicals in reusable menstrual products. "Since reusable products are on the rise due to their increased sustainability compared to single-use products, it's important to ensure that these products are safe. This is crucial, especially for adolescents and young women, who are more vulnerable to potential negative health effects," said paper author and chemist professor Marta Venier of Indiana University in a statement. "Feminine hygiene products stay in contact with the skin for extended periods of time, and the risks from the dermal absorption of PFAS, especially neutral PFAS, are not well understood." What Are PFAS and Why Are They Concerning? PFAS are synthetic chemicals used for their water, stain and heat-resistant properties. However, they are known to accumulate in the human body over time and have been linked to serious health conditions, including hormone disruption, cancer and immune system dysfunction. "One of the most abundant PFAS detected in products from the North American market is 8:2 FTOH, a chemical that was voluntarily phased out in food packaging by manufacturers in accordance with the FDA due to persistence in the body after dietary exposure," explained Sydney Brady, a Ph.D. student in Venier's lab. "Notably, 8:2 FTOH can be transformed into more toxic PFOA once inside the body." Newsweek reached out to Dr. Olivia Ahn, a former NHS doctor based in the U.K., who described the idea of chemicals and microplastics entering women's bodies as "unsettling." "It's a serious concern that demands urgent attention from everyone involved – from the companies making these products to the regulators overseeing them," she said. Ahn, founder of the sustainable femcare brand FLUUS—which developed the world's first certified flushable, microplastics- and glue-free sanitary pad made from non-woven natural materials—explained how these substances are absorbed through sensitive tissues. She said: "The vaginal tissue isn't like the skin on your arm—it's incredibly delicate and acts like a fast track directly to your bloodstream. It's highly absorbent, meaning chemicals can quickly get into your system without being filtered by your liver or digestive system in the usual way. "This pathway is so efficient that it's even used in medicine for quick drug delivery. This unique sensitivity is precisely why we must be extra vigilant about the chemical makeup of products designed for intimate use. What you put there really matters for your overall health." Environmental Implications of Reusables While reusable menstrual products are seen as a sustainable alternative to disposables, they still end up in landfills. Once there, PFAS can leach into the soil and water, posing a wider environmental hazard. These findings underline the need for greater transparency in product manufacturing and labeling. "Consumers should know that not everything that is in a product is listed on the package," Venier added. "Increased transparency from manufacturers would help consumers make informed decisions about what they're purchasing for themselves and their families." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about PFAS? Let us know via health@ References Wang, Z., Peebles, E., Baird, D. D., Jukic, A. M. Z., Wilcox, A. J., Curry, C. L., Fischer-Colbrie, T., Onnela, J.-P., Williams, M. A., Hauser, R., Coull, B. A., & Mahalingaiah, S. (2025). Menstrual product use patterns in a large digital cohort in the United States: Variations by sociodemographic, health, and menstrual characteristics. American Journal of Obstetrics and Gynecology. Wicks, A., Brady, S., Whitehead, H. D., Hedman, T., Zachritz, A., Venier, M., & Peaslee, G. F. (2025). Per- and Polyfluoroalkyl Substances in Reusable Feminine Hygiene Products. Environmental Science & Technology Letters.


Washington Post
13 minutes ago
- Washington Post
I'm a Democrat. RFK Jr. is right about food additives.
Rosa DeLauro, a Democrat, represents Connecticut's 3rd Congressional District in the U.S. House. Health and Human Services Secretary Robert F. Kennedy Jr. and I don't agree on much — but we both know the Food and Drug Administration needs to get serious about food regulation. Most Americans have no idea that the FDA puts synthetic and potentially carcinogenic additives in the same category as salt. It's called GRAS — 'generally recognized as safe' — yet it's anything but.